Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C

European Journal of Pharmacology

Volumn 644, Issue 1-3, 2010, Pages 41-48

  González Lobato, Lucía ^a   Real, Rebeca ^a   Prieto, Julio G ^a   Álvarez, Ana I ^a   Merino, Gracia ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

BCRP ABCG2; Cytotoxicity; Fumitremorgin C; Inhibition; Transport

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FUMITREMORGIN C; MITOXANTRONE; NITROFURANTOIN;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SCREENING; DRUG TRANSPORT; EMBRYO; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPECIES DIFFERENCE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; DOGS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MITOXANTRONE; MYCOTOXINS; NEOPLASM PROTEINS; NITROFURANTOIN; PORPHYRINS; SPECIES SPECIFICITY; TRANSDUCTION, GENETIC;

EID: 77955770550     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.016     Document Type: Article

References (42)

1. Allen J.D., Brinkhuis R.F., Wijnholds J., Schinkel A.H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone or doxorubicin. Cancer Res. 1999, 59:4237-4241.
2. Allen J.D., Brinkhuis R.F., van Deemter L., Wijnholds J., Schinkel A.H. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000, 60:5761-5766.
3. Allen J.D., Loevezijn A., Lakhai J., van der Valk M., Tellingen O., Reid G., Schellens J., Koomen G., Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 2002, 1:417-425.
4. Bardsley, W.G., 2001. SIMFIT. Simulation, fitting, statistics and plotting. Version 5.4. Reference Manual.
5. Bram E.E., Adar Y., Mesika N., Sabisz M., Skladanowski A., Assaraf Y.G. Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2. Mol. Pharmacol. 2009, 75:1149-1159.
6. Ceckova M., Vackova Z., Radilova H., Libra A., Buncek M., Staud F. Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol. In Vitro 2008, 22:1846-1852.
7. Choi M.K., Kim H., Han Y.H., Song I.S., Shim C.K. Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica 2009, 39:171-181.
8. Clark R., Kerr I.D., Callaghan R. Multiple drug binding sites on the R482G isoform of the ABCG2 transporter. Br. J. Pharmacol. 2006, 149:506-515.
9. Cole R.J., Cox R.H. Tremorgin group. Handbook of Toxic Fungal Metabolites 1981, 355-509. Academic Press, New York.
10. Cusatis G., Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008, 9:1005-1009.
11. Gerk P.M., Moscow J.A., McNamara P.J. Basolateral active uptake of nitrofurantoin in the CIT3 cell culture model of lactation. Drug Metab. Dispos. 2003, 31:691-693.
12. Garimella T.S., Ross D.D., Eiseman J.L., Mondick J.T., Joseph E., Nakanishi T., Bates S.E., Bauer K.S. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors. Cancer Chemother. Pharmacol. 2005, 55:101-109.
13. Giri N., Agarwal S., Shaik N., Pan G., Chen Y., Elmquist W.F. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab. Dispos. 2009, 37:560-570.
14. Hauswald S., Duque-Afonso J., Wagner M.M., Schertl F.M., Lübbert M., Peschel C., Keller U., Licht T. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 2009, 15:3705-3715.
15. Ito K. ABCC2/Abcc2 transport property in different species and its modulation by heterogeneous factors. Drug Metab. Pharmacokinet. 2008, 23:394-405.
16. Johnson J.L., Ahmad A., Khan S., Wang Y.F., Abu-Qare A.W., Ayoub J.E., Zhang A., Ahmad I. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 799:149-155.
17. Katoh M., Suzuyama N., Takeuchi T., Yoshitomi S., Asahi S., Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 2006, 95. 2673-1683.
18. Li H., Jin H.E., Kim W., Han Y.H., Kim D.D., Chung S.J., Shim C.K. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm. Res. 2008, 25:2601-2612.
19. Li M., Yuan H., Li N., Song G., Zheng Y., Baratta M., Hua F., Thurston A., Wang J., Lai Y. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. Eur. J. Pharm. Sci. 2008, 35:114-126.
20. Mathew G., Timm E.A., Sotomayor P., Godoy A., Montecinos V.P., Smith G.J., Huss W.J. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009, 8:1053-1061.
21. Merino G., Álvarez A.I., Pulido M.M., Molina A.J., Schinkel A.H., Prieto J.G. Breast cáncer resistance protein (BCRP/ABCG2) transport fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics and milk secretion. Drug Metab. Dispos. 2006, 34:690-695.
22. Merino G., Real R., Baro M.F., Gonzalez-Lobato L., Prieto J.G., Alvarez A.I., Marques M.M. Natural allelic variants of bovine ABCG2 transporter: increased activity of the S581 variant and development of tools for the discovery of new ABCG2 inhibitors. Drug Metab. Dispos. 2009, 37:5-9.
23. Minderman H., Suvannasankha A., O'Loughlin K.L., Scheffer G.L., Scheper R.J., Robey R.W., Baer M.R. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 2002, 48:59-65.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983, 65:55-63.
25. Noguchi K., Katayama K., Mitsuhashi J., Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev. 2009, 61:26-33.
26. Paturi D.K., Kwatra D., Ananthula H.K., Pal D., Mitra A.K. Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int. J. Pharm. 2010, 384:32-38.
27. Pavek P., Merino G., Wagenaar E., Bolscher E., Novotna M., Jonker J.W., Schinkel A.H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazol(4, 5-b)pyridine, and transport of cimetidine. J. Pharm. Exp. Ther. 2005, 312:144-152.
28. Rabindran S., Ross D., Doyle L., Yang W., Greenberger L. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60:47-50.
29. Rivers F., O'Brien T.J., Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur. J. Pharmacol. 2008, 598:1-8.
30. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., Bates S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004, 64:1242-1246.
31. Robey R.W., Steadman K., Polgar O., Bates S.E. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol. Ther. 2005, 4:187-194.
32. Sarkadi B., Homolya L., Szakács G., Váradi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 2006, 86:1179-1236.
33. Solazzo M., Fantappiè O., D'Amico M., Sassoli C., Tani A., Cipriani G., Bogani C., Formigli L., Mazzanti R. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res. 2009, 69:7235-7242.
34. Susanto J., Lin Y.H., Chen Y.N., Shen C.R., Yan Y.T., Tsai S.T., Chen C.H., Shen C.N. Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells. PLoS ONE 2008, 3:e4023.
35. Takenaka K., Morgan J.A., Scheffer G.L., Adachi M., Stewart C.F., Sun D., Leggas M., Ejendal K.F., Hrycyna C.A., Schuetz J.D. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 2007, 67:6965-6972.
36. Taub M.E., Podila L., Ely D., Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab. Dispos. 2005, 33:1679-1687.
37. Tiwari A.K., Sodani K., Wang S.R., Kuang Y.H., Ashby C.R., Chen X., Chen Z.S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 2009, 78:153-161.
38. Usuda J., Tsunoda Y., Ichinose S., Ishizumi T., Ohtani K., Maehara S., Ono S., Tsutsui H., Ohira T., Okunaka T., Furukawa K., Sugimoto Y., Kato H., Ikeda N. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. Lung Cancer 2010, 67:198-204.
39. Vlaming M.L., Lagas J.S., Schinkel A.H. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev. 2009, 61:14-25.
40. Zhang Y., Gupta A., Wang H., Zhou L., Vethanayagam R.R., Unadkat J.D., Mao Q. BCRP Transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 2005, 22:2023-2034.
41. Zheng L.S., Wang F., Li Y.H., Zhang X., Chen L.M., Liang Y.J., Dai C.L., Yan Y.Y., Tao L.Y., Mi Y.J., Yang A.K., To K.K., Fu L.W. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS ONE 2009, 4:e5172.
42. Zimmermann C., van de Wetering K., van de Steeg E., Wagenaar E., Vens C., Schinkel A.H. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab. Dispos. 2008, 36:631-639.